NEJM This Week — April 23, 2026

This week's episode of NEJM This Week explores several pivotal advances and challenges in modern medicine. Key studies include a landmark trial showing that a triple-pill antihypertensive regimen (telmisartan, amlodipine, indapamide) significantly reduces recurrent stroke risk after intracerebral hemorrhage, though blood pressure control remains suboptimal in over half the patients, highlighting the need for systemic care coordination. Another study finds that nirmatrelvir-ritonavir does not reduce hospitalization or death in vaccinated, higher-risk outpatients with COVID-19—likely due to pre-existing immunity and variant changes—though it still shows antiviral activity and may benefit select patients. In prostate cancer, transdermal estradiol patches prove non-inferior to standard hormone therapy with fewer hot flashes but more gynecomastia. A large trial finds no survival benefit for ketamine over etomidate in critically ill intubated adults. The episode also examines broader systemic issues: Utah’s AI-driven prescription renewal pilot raises questions about autonomy, regulation, and FDA oversight; concerns over 'killer acquisitions' in pharma threaten innovation; and calls to strengthen the Pediatric Research Equity Act to close gaps in child drug testing. A poignant case study of an 86-year-old woman with liver abscesses underscores diagnostic complexity, while a narrative on 'goals of care' emphasizes the transformative power of cultural connection in end-of-life care. Climate change’s growing impact on health is illustrated through cases of smoke inhalation and Vibrio vulnificus infections. Key takeaways include: 1) Aggressive, system-wide blood pressure control is essential post-hemorrhagic stroke, even if current tools fall short; 2) Antivirals like nirmatrelvir-ritonavir should be used selectively in high-risk, vulnerable patients despite reduced efficacy in the vaccinated; 3) AI in healthcare must balance innovation with regulatory rigor and patient safety; 4) Pharmaceutical mergers can stifle competition and innovation, requiring stronger antitrust enforcement; 5) Pediatric drug development needs stronger legal mandates to ensure testing across all relevant age groups; 6) Effective end-of-life care often hinges on human connection, not just clinical protocol; 7) Climate change is already driving new and severe clinical presentations. The episode maintains a balanced, forward-looking tone, emphasizing both progress and persistent systemic challenges.